Novo Nordisk A/S files for regulatory approval of liraglutide 3 mg for the treatment of obesity


Bagsvaerd, Denmark, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Bagsværd, Denmark, 20 December 2013 - Novo Nordisk today announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities. The company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA).

 

Further information

Media:
Mike Rulis +45 4442 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Frank Daniel Mersebach +45 3079 0604 fdni@novonordisk.com
Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Jannick Lindegaard (US) +1 609 235 8567 jlis@novonordisk.com

Company announcement No 78 / 2013 http://hugin.info/2013/R/1751528/590496.pdf

HUG#1751528